Genital Human Papilloma Virus (HPV) infection is the most common sexually transmitted infection (STI) in the United States and worldwide. Over 50% of sexually active adolescents will become infected with HPV. HPV infection is strongly associated with the development of anogenital dysplasias and invasive cancers. Because HPV is a STI, optimal prevention in women will depend on prevention in their partners as well. Males remain a significant reservoir of HPV and vaccinating them will be essential for rapidly preventing transmission of HPV in the community.
P1085 is a sub study of P1047, which investigated the safety and immunogenicity of Quadrivalent HPV (QHPV) in HIV-infected girls and boys, age 7 to 12 years of age. This study was a placebo-controlled trial that compared a recommended three dose schedule of QHPV in one study arm (Arm A) with an arm that received placebo (Arm B). P1047 has thus far demonstrated that QHPV can be safely administered to human immunodeficiency virus (HIV)-infected boys and girls and will stimulate seroconversion in more than 95% of vaccinees. However, these antibody levels were 30-50% lower than those achieved in children without HIV infection. Since levels of vaccine-induced antibodies decline with time after vaccination, it is uncertain if vaccine-induced immunity will be life-long. This concern is supported by some evidence that naturally acquired HPV-specific antibody might decline to a level that will permit re-infection. Comparative persistence data for HPV-specific antibody is available for 5-6 years after vaccination of almost 1000 children without HIV infection (manufacturer’s data, unpublished), but there is no such information available from HIV-infected vaccinees.
We seek to determine the long-term durability and kinetics of the vaccine-induced HPV-type-specific antibody and CMI responses in HIV-infected children that were, and are being, immunized in P1047. These subjects are a unique cohort that will allow us to approach this specific clinical issue.
- Grizzlies' Randolph revved to return, healthy Rudy Gay feels 'like a rookie again'
- Only One Week Left for a Chance to Win a $1,000 Gift Card in...
- Trial of Computerized MET for Adolescent Substance Use
- The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
- LGBT-Themed Primetime TV Hits Record High (Report)
- GOP gay group honors Sen. Brown for backing ban repeal
- Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination
- Randomized Controlled Trial of Trauma-focused CBT in Tanzania and Kenya
- Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects
- Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care